{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:47:33Z","timestamp":1789040853078,"version":"build-2803163510"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Health and Medical Research Council of Australia","award":["1112125"],"award-info":[{"award-number":["1112125"]}]},{"name":"Foundation Lijf en Leven"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Although effective in preventing tumour growth, angiogenesis inhibitors cause off-target effects including cardiovascular toxicity and renal injury, most likely via endothelin (ET)-1 up-regulation. ET-1 via stimulation of the ETA receptor has pro-hypertensive actions whereas stimulation of the ETB receptor can elicit both pro- or anti-hypertensive effects. In this study, our aim was to determine the efficacy of selective ETA vs. dual ETA\/B receptor blockade for the prevention of angiogenesis inhibitor-induced hypertension and albuminuria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>Male Wistar Kyoto (WKY) rats were treated with vehicle, sunitinib (angiogenesis inhibitor; 14\u2009mg\/kg\/day) alone or in combination with macitentan (ETA\/B receptor antagonist; 30\u2009mg\/kg\/day) or sitaxentan (selective ETA receptor antagonist; 30 or 100\u2009mg\/kg\/day) for 8\u2009days. Compared with vehicle, sunitinib treatment caused a rapid and sustained increase in mean arterial pressure of \u223c25\u2009mmHg. Co-treatment with macitentan or sitaxentan abolished the pressor response to sunitinib. Sunitinib did not induce endothelial dysfunction. However, it was associated with increased aortic, mesenteric, and renal oxidative stress, an effect that was absent in mesenteric arteries of the macitentan and sitaxentan co-treated groups. Albuminuria was greater in the sunitinib- than vehicle-treated group. Co-treatment with sitaxentan, but not macitentan, prevented this increase in albuminuria. Sunitinib treatment increased circulating and urinary prostacyclin levels and had no effect on thromboxane levels. These increases in prostacyclin were blunted by co-treatment with sitaxentan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results demonstrate that both selective ETA and dual ETA\/B receptor antagonism prevents sunitinib-induced hypertension, whereas sunitinib-induced albuminuria was only prevented by selective ETA receptor antagonism. In addition, our results uncover a role for prostacyclin in the development of these effects. In conclusion, selective ETA receptor antagonism is sufficient for the prevention of sunitinib-induced hypertension and renal injury.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cvr\/cvz260","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T19:24:49Z","timestamp":1569957889000},"page":"1779-1790","source":"Crossref","is-referenced-by-count":38,"title":["Selective ETA vs. dual ETA\/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats"],"prefix":"10.1093","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-9040","authenticated-orcid":false,"given":"Katrina M","family":"Mirabito Colafella","sequence":"first","affiliation":[{"name":"Cardiovascular Disease Program, Department of Physiology, Biomedicine Discovery Institute, Monash University, 26 Innovation Walk, Melbourne, VIC 3800, Australia"},{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla B","family":"Neves","sequence":"additional","affiliation":[{"name":"Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto C","family":"Montezano","sequence":"additional","affiliation":[{"name":"Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M","family":"Garrelds","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Program, Department of Physiology, Biomedicine Discovery Institute, Monash University, 26 Innovation Walk, Melbourne, VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"van Veghel","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Program, Department of Physiology, Biomedicine Discovery Institute, Monash University, 26 Innovation Walk, Melbourne, VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"de Vries","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Program, Department of Physiology, Biomedicine Discovery Institute, Monash University, 26 Innovation Walk, Melbourne, VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9138-6639","authenticated-orcid":false,"given":"Estrellita","family":"Uijl","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Program, Department of Physiology, Biomedicine Discovery Institute, Monash University, 26 Innovation Walk, Melbourne, VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J","family":"Baelde","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton H","family":"van den Meiracker","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-0887","authenticated-orcid":false,"given":"Rhian M","family":"Touyz","sequence":"additional","affiliation":[{"name":"Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A H Jan","family":"Danser","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorie","family":"Versmissen","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"2020072414264765000_cvz260-B1","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/cvr\/cvz022","article-title":"Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension","volume":"115","author":"Versmissen","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2020072414264765000_cvz260-B2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/HYPERTENSIONAHA.116.07618","article-title":"Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition","volume":"68","author":"van den Meiracker","year":"2016","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","article-title":"Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress","volume":"59","author":"Kappers","year":"2012","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/HYPERTENSIONAHA.115.05435","article-title":"Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib","volume":"66","author":"Lankhorst","year":"2015","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B7","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/cvr\/cvz021","article-title":"Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury","volume":"115","author":"Neves","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2020072414264765000_cvz260-B9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FJC.0000000000000283","article-title":"Vascular effects of endothelin receptor antagonists depends on their selectivity for ETA versus ETB receptors and on the functionality of endothelial ETB receptors","volume":"66","author":"Iglarz","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"2020072414264765000_cvz260-B10","doi-asserted-by":"crossref","first-page":"e91897.","DOI":"10.1371\/journal.pone.0091897","article-title":"Sflt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice","volume":"9","author":"Amraoui","year":"2014","journal-title":"PLoS One"},{"key":"2020072414264765000_cvz260-B11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/HYPERTENSIONAHA.114.03315","article-title":"Downregulation of microvascular endothelial type b endothelin receptor is a central vascular mechanism in hypertensive pregnancy","volume":"64","author":"Mazzuca","year":"2014","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00060.2009","article-title":"Regulation of blood pressure and salt homeostasis by endothelin","volume":"91","author":"Kohan","year":"2011","journal-title":"Physiol Rev"},{"key":"2020072414264765000_cvz260-B14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"Vegfr (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.lfs.2014.02.018","article-title":"Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension","volume":"118","author":"Iglarz","year":"2014","journal-title":"Life Sci"},{"key":"2020072414264765000_cvz260-B16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yrtph.2012.05.017","article-title":"An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (thelin(r)), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension","volume":"64","author":"Owen","year":"2012","journal-title":"Regul Toxicol Pharmacol"},{"key":"2020072414264765000_cvz260-B17","doi-asserted-by":"crossref","first-page":"H984","DOI":"10.1152\/ajpheart.2001.280.3.H984","article-title":"Et(a)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat","volume":"280","author":"Podesser","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2020072414264765000_cvz260-B18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00003495-200767050-00007","article-title":"Sitaxentan: in pulmonary arterial hypertension","volume":"67","author":"Scott","year":"2007","journal-title":"Drugs"},{"key":"2020072414264765000_cvz260-B19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/pupt.2000.0237","article-title":"Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active et(a) receptor antagonist","volume":"13","author":"Tilton","year":"2000","journal-title":"Pulm Pharmacol Ther"},{"key":"2020072414264765000_cvz260-B20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/FJC.0b013e3181993493","article-title":"Eta receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor abt-869 in telemetry-instrumented rats","volume":"53","author":"Banfor","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"2020072414264765000_cvz260-B21","doi-asserted-by":"crossref","first-page":"16066","DOI":"10.1016\/S0021-9258(18)41966-7","article-title":"Polar secretion of endothelin-1 by cultured endothelial cells","volume":"267","author":"Wagner","year":"1992","journal-title":"J Biol Chem"},{"key":"2020072414264765000_cvz260-B22","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.2353\/ajpath.2006.051331","article-title":"Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling","volume":"169","author":"Morigi","year":"2006","journal-title":"Am J Pathol"},{"key":"2020072414264765000_cvz260-B23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0002-9440(10)62350-4","article-title":"In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies","volume":"166","author":"Morigi","year":"2005","journal-title":"Am J Pathol"},{"key":"2020072414264765000_cvz260-B24","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/01.HYP.0000149249.09147.b4","article-title":"Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition","volume":"44","author":"Ortmann","year":"2004","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B25","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.110.156570","article-title":"Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat","volume":"56","author":"Saleh","year":"2010","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/jpet.111.178988","article-title":"Distinct actions of endothelin a-selective versus combined endothelin a\/b receptor antagonists in early diabetic kidney disease","volume":"338","author":"Saleh","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"2020072414264765000_cvz260-B27","doi-asserted-by":"crossref","first-page":"F1185","DOI":"10.1152\/ajprenal.00442.2007","article-title":"Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells","volume":"294","author":"Collino","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020072414264765000_cvz260-B28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/ars.2013.5244","article-title":"Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress","volume":"20","author":"Lankhorst","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"2020072414264765000_cvz260-B29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lfs.2014.02.032","article-title":"Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro","volume":"118","author":"Star","year":"2014","journal-title":"Life Sci"},{"key":"2020072414264765000_cvz260-B30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2125.2000.00171.x","article-title":"Pharmacokinetics and pharmacodynamic effects of abt-627, an oral eta selective endothelin antagonist, in humans","volume":"49","author":"Verhaar","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"2020072414264765000_cvz260-B31","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/01.HYP.31.3.766","article-title":"Chronic oral endothelin type a receptor antagonism in experimental heart failure","volume":"31","author":"Borgeson","year":"1998","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00005344-199707000-00006","article-title":"Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs","volume":"30","author":"Burke","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"2020072414264765000_cvz260-B33","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/01.HYP.30.6.1578","article-title":"Role of endothelin in hypertension of experimental chronic renal failure","volume":"30","author":"Potter","year":"1997","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.HYP.30.1.29","article-title":"Role for endothelin-1 in angiotensin ii-mediated hypertension","volume":"30","author":"Rajagopalan","year":"1997","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/HYPERTENSIONAHA.117.10225","article-title":"Pazopanib-induced hypertension in patients with renal cell carcinoma is associated with low urine excretion of no metabolites","volume":"71","author":"Tinning","year":"2018","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/01.HYP.0000138070.47616.9d","article-title":"Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?","volume":"44","author":"Touyz","year":"2004","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B37","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/ars.2013.5302","article-title":"Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research","volume":"20","author":"Montezano","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"2020072414264765000_cvz260-B38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"2020072414264765000_cvz260-B39","doi-asserted-by":"crossref","first-page":"105918.","DOI":"10.1155\/2012\/105918","article-title":"A comprehensive review of hypertension in pregnancy","volume":"2012","author":"Mustafa","year":"2012","journal-title":"J Pregnancy"},{"key":"2020072414264765000_cvz260-B40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1042\/CS20171366","article-title":"Endothelin type B (ETB) receptors: friend or foe in the pathogenesis of pre-eclampsia and future cardiovascular disease (CVD) risk?","volume":"132","author":"Mirabito Colafella","year":"2018","journal-title":"Clin Sci"},{"key":"2020072414264765000_cvz260-B41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"2020072414264765000_cvz260-B42","doi-asserted-by":"crossref","first-page":"1374.","DOI":"10.1016\/S0140-6736(80)92443-5","article-title":"Reduced prostacyclin production in pre-eclampsia","volume":"2","author":"Downing","year":"1980","journal-title":"Lancet"},{"key":"2020072414264765000_cvz260-B43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0090-6980(80)90010-6","article-title":"Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia","volume":"20","author":"Remuzzi","year":"1980","journal-title":"Prostaglandins"},{"key":"2020072414264765000_cvz260-B44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/01.CIR.75.5.956","article-title":"Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension","volume":"75","author":"Fitzgerald","year":"1987","journal-title":"Circulation"},{"key":"2020072414264765000_cvz260-B45","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-017-0823-0","article-title":"Aspirin for prevention of preeclampsia","volume":"77","author":"Atallah","year":"2017","journal-title":"Drugs"},{"key":"2020072414264765000_cvz260-B46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0952-3278(03)00086-3","article-title":"9 alpha, 11 beta-prostaglandin F2 in pregnancies at high risk for hypertensive disorders of pregnancy, and the effect of acetylsalicylic acid","volume":"69","author":"Vainio","year":"2003","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2020072414264765000_cvz260-B47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000009975","article-title":"Urinary PGE2 and PGF2alpha levels and renal functions in preeclampsia","volume":"45","author":"Vural","year":"1998","journal-title":"Gynecol Obstet Invest"},{"key":"2020072414264765000_cvz260-B48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1161\/01.HYP.5.1.105","article-title":"Preeclampsia\u2014a state of prostaglandin deficiency? Urinary prostaglandin excretion, the renin-aldosterone system, and circulating catecholamines in preeclampsia","volume":"5","author":"Pedersen","year":"1983","journal-title":"Hypertension"},{"key":"2020072414264765000_cvz260-B49","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1055\/s-2007-994334","article-title":"Urinary cyclic GMP, endothelin, and prostaglandin E2 in normal pregnancy and preeclampsia","volume":"14","author":"Clark","year":"1997","journal-title":"Amer J Perinatol"},{"key":"2020072414264765000_cvz260-B50","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0002-9378(87)80162-X","article-title":"Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets","volume":"157","author":"Fitzgerald","year":"1987","journal-title":"Am J Obstet Gynecol"},{"key":"2020072414264765000_cvz260-B51","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1113\/jphysiol.2008.161430","article-title":"Endothelium-dependent contractions: when a good guy turns bad!","volume":"586","author":"Vanhoutte","year":"2008","journal-title":"J Physiol"},{"key":"2020072414264765000_cvz260-B52","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/sj.bjp.0706390","article-title":"Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin","volume":"146","author":"Gluais","year":"2005","journal-title":"Br J Pharmacol"},{"key":"2020072414264765000_cvz260-B53","doi-asserted-by":"crossref","first-page":"H2198","DOI":"10.1152\/ajpheart.00507.2008","article-title":"Aging and prostacyclin responses in aorta and platelets from WKY and SHR rats","volume":"295","author":"Gomez","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2020072414264765000_cvz260-B54","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/bjp.2008.200","article-title":"Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane a2 and prostacyclin","volume":"154","author":"Xavier","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2020072414264765000_cvz260-B55","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1476-5381.2008.00060.x","article-title":"Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors","volume":"156","author":"Feletou","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2020072414264765000_cvz260-B56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.apha.2016.04.006","article-title":"Endothelium-dependent contractions: prostacyclin and endothelin-1, partners in crime?","volume":"77","author":"Baretella","year":"2016","journal-title":"Adv Pharmacol"},{"key":"2020072414264765000_cvz260-B57","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.18632\/oncotarget.3437","article-title":"Cyclooxygenase-2 blockade can improve efficacy of vegf-targeting drugs","volume":"6","author":"Ben-Batalla","year":"2015","journal-title":"Oncotarget"},{"key":"2020072414264765000_cvz260-B58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of cox-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2005","journal-title":"J Clin Invest"},{"key":"2020072414264765000_cvz260-B59","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators","volume":"338","author":"Krum","year":"1998","journal-title":"N Engl J Med"},{"key":"2020072414264765000_cvz260-B60","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1517\/14740338.2012.714770","article-title":"Safety and efficacy evaluation of Ambrisentan in pulmonary hypertension","volume":"11","author":"Vizza","year":"2012","journal-title":"Expert Opin Drug Saf"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvz260\/30333902\/cvz260.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/116\/10\/1779\/33529849\/cvz260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/116\/10\/1779\/33529849\/cvz260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T23:33:17Z","timestamp":1611444797000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/116\/10\/1779\/5583774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,4]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvz260","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,1]]},"published":{"date-parts":[[2019,10,4]]}}}